Drugs / ART352-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04378543 | Sep 2020 → Apr 2022 | spondylolisthesis | Ankasa Regenerative Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART352-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04378543 ↗ |
| Modality | Protein / enzyme biologic | “a liposomal formulation of recombinant human Wnt3A protein” NCT04378543 ↗ |
| Route | Other | “applied ex vivo, to harvested autologous bone grafts (autograft)” NCT04378543 ↗ |